New trial available: Click on any alert below and access our regulatory alerts and get timely notifications sent to your inbox for 7 days.
10th May 2023
New Zealand: Tilray FS THC 5: CBD 20, a cannabis oral solution, has been verified by the Medicinal Cannabis Agency as meeting the minimum quality standard required to be supplied in New Zealand.
20th April 2023
New Zealand: Medleaf High THC GG#4, a dried cannabis flower used to make tea, has been verified by the Medicinal Cannabis Agency as meeting the minimum quality standard required to be supplied in New Zealand.
3rd February 2023
19th January 2023
New Zealand: Changes to the Medicinal Cannabis Scheme, related to product standards and approvals, are set to be presented by the Ministry of Health, according to NORML. Among the measures, expected to come into effect in the second half of the year, are multi-year and multi-site licensing and allowing the supply of batch-tested crops.
14th November 2022
10th October 2022
7th October 2022
13th September 2022
New Zealand: Two CBD liquids for oral use, Helius CBD25 Full Spectrum and Helius CBD100 Full Spectrum, have been verified by the Medical Cannabis Agency as meeting the minimum quality standard required for them to be supplied in New Zealand.
10th August 2022
New Zealand: After criticism from the industry for being too restrictive, the Health Ministry has said it will review the Medicinal Cannabis Scheme and release a consultation document later this month, press reports. The scheme came into operation in 2020, intended to improve patients’ access to quality medicinal cannabis.
29th June 2022
New Zealand: A second new medical cannabis flower from MW Pharma Limited, trading as NUBU Pharmaceuticals, has been approved by the Ministry of Health. The product, which contains 200 mg/g (20%) THC, is intended to be inhaled via a vaporiser.
19th May 2022
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.